Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21575503 | 0.92 | TLR9 (0.42) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL21387486 | 0.92 | RIPK1 (0.41) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL2261640 | 0.92 | RIPK1 (0.44) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL2261643 | 0.92 | RIPK1 (0.44) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL10091219 | 0.92 | RIPK1 (0.44) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL23074226 | 0.92 | RIPK1 (0.41) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL18466652 | 0.91 | MCHR1 (0.50) | SLC6A2SLC6A4SLC6A3KCNN4METAP2 | |
| SCHEMBL28673516 | 0.91 | KCNN4 (0.42) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL9561997 | 0.89 | RIPK1 (0.46) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 | |
| SCHEMBL2266633 | 0.89 | RIPK1 (0.39) | RIPK1SLC6A2SLC6A4SLC6A3KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | RIPK1 4294/4885SLC6A2 661/4885SLC6A4 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.